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ABSTRACT
The possible role of beta-carotene as a protective
nutrient against cancer is reviewed. Human prospective
and retrospective studies strongly indicate that
beta-carotene protects against lung cancer and probably
against stomach cancer. It may also be protective
against cancer of the ovary, cervix, breast and other
cancers, but not the colon or rectum. The protective
factor appears to be beta-carotene itself, rather than
total vitamin A.. Experiments using a variety of animal
models also show that beta-carotene is anti-
carcinogenic and appears to act at several stages of
the process. Possible mechanisms of action are
discussed, namely that it must first be converted to
vitamin A, that it alters carcinogen metabolism, that
it is an anti-oxidant and that it enhances the immune
defenses.
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INTRODUCTION
In 1981, Peto et al. (1) reinterpreted various data and
hypothesized that beta-carotene had a specific preventive action
against cancer. This sparked much active interest and numerous
reports have now appeared to shine much new light on the question.
The hypothesis resembles Burkitt's concept of dietary fiber in that
what started with the great virtue of simplicity has proved, on
more careful scrutiny, to be considerably more complex (2).
Correspondence and requests for reprints to Dr. T.K. Basu.
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The major par.t_os_tf1e_ey~dence of the preventive effect of
beta-c~~~__cQ~fr9m_~tudie$-- on -=hQ:rnan~ Wl-t1i ai1d wIthout
~-'-Such-evidence, more often than not, presents serious
problems of.interpretation (3). FE~que,ntly, the parameter measured
i~ diet:ary tot"1g=-~vitamin A, (ie. retinol pl'us---beta~-carotene).
Howe'ver, retinol and. its- analogues ,.,~-!so have anti-carcfnogenic
properties (4-6). Even where beta-carotEme": nas been specifically
measured, it is also strongly__associat~9 -witb t1!~_~c~ns_umption of
green and y-ellow,.v_~g~t~b.les. Thus the true protective factor-mIght
be beta-carotene, dietary fiber indoles, phenols, glucuronidase
inhibitors, or even a low intake of meat. On top of these problems
dietary assessment has an inherent lack of precision. Furthermore,
if dietary assessment done_-_on, patients-who- a1ready..have__cancer
(retrospective studies), t~en the disease may h~ye. aff_ected the
'diet (or the sUbj-e~ct"s memory of his diet). .---
--~
-,
--"
'
--
.-
Often beta-carotene status ha~,- been_quantitated
- on,--the---Pa~J..s
of blood .a~<?:lysis. unl'iK~~=.J:>lo~~ retinol, the blood level of
beta-carotene is .?_religJ:~le, iI)dex- of dietary intake (7,8). Even
so, in the context of cancer studies.-'it'-may"merely be an indirect
measure of other_, dietary .components.
-
~-.-
'-
Another problem is~__the___matching___"o~ cases and_, controls.
Ideally, an array of possibly relevant - 'factors' should be
considered, either in the matching itself, or subsequently by
analyzing the results using multiple regression. Smoking is
partig\.llarly__impor1;..ant. Apart from its close association with
se,veral types of cancer, smokers have a below averag,e, dietary
intake (9) and blood level (10-14) of carotene. .-
LUNG CANCER
Di~~ary or blood indicators of be.t-a-carotene intake are
closely related to lung cancerr:J_s,k.(Table 1). The evidence
strongly suggests that persons' wi-th a low intake of beta-carotene
are at a 30 to 220% higher risk than otherwise similar people whose
intake is relatively high (9,12.13,15-23). .
Several of the studies provided data on the different
histological types of lung cancer. Beta-carotene is most
protective with squamous cell and small cell carcinoma but is
generally not protective against adenocarcinoma (15,19,22-24).
The question arises as to what is the true protective factor.
'1:h.e 0i1iY' two_E.!a~!-e_._C;~!:1sl1~i~;£es_,_are'--b~carotene i.tself and
~qt~l_~l~amin A. Good evidence points to the former. First, blood
retJ-nol ,leve1s have---little or no relation~hip with 1un9-- cance'r
(13,15,25,26). Menkes et al. (15) pointed out--t:h-at-'onlY'stuale's
using small numbers of subjects have repoJ;t.~d a relations_h,i,-p, with
luhg--cancer riSK'and'vitamin A. Similarly, wherediet'ary- carotene
and retl.nol have beEm simuI taneousIy measured, it is the former
TABLE 1
Relationship Between Measures of Beta-carotene Status and Risk of Lung Cancer
No. of
cancers No. of Type of
t
Measurement and sex controls study* Relative risk or case-control difference Place Reference
serum beta-
carotene 99 H/F 196 P 2.2, I.7, 1.8, 1.2, 1.0 (p ..0.04) }larylnnd 15
plasr.la beta-
102flcarotene 35 H P 38% lower (p
"
0.0006) Basel 12
serum beta-
carotene 74 N 302 P 2.2, 2.4, 1.2, 1.5, 1.0 (p ..O. 04) Hawaii 13
dietary tot.,l
1. a (NS)
§
carotene 447 H/F 759 R 1.3, 1.2,
-
New Hexico 16 CJ
I'T1dietary total
**
-i
carotene 364 H/F 627 R 1.6, 1.2, 1.1, 1.0 (p < 0.05) Hawaii 17
:to
.
dietllry total n;r::.
vitamin At t 514 tI 1238 R 1.4, 1.0, 1.0 (p < 0.05) Roswell Park 18 ;;00
dietnry total -iI'T1
vitnmin A 104 t1/F 16,713 P 1.9, 1.0 (p ..0.02) Norway 19 ::z
dietary totlll I'T1
IHI ;r::.
vitamin A 100 }l/F 173
It
R overall, slightly lower London 20 z
yellow/ green 6ll H I 22 , 261
~I
1.3, 1.0 0
vegetables 196 F 142.857' P 1.5, 1.0 Japlln
. 21
n;r::.
dieta.rytotal J Zn
carotene 33 H 1954 P 7.0, 5.5, 3.0, 1.0 (p
=
0.003) Chicnr;o 9 I'T1
dietary total ;::0
carotene 763 H 900 R 1.3, 1.3, 1.0 (p .. 0.05) New Jersey 22
dietary betll-
carotene 216 F 216 R 2.5, 1.3, 0.8, 1.0 (p < 0.05) Los Angeles 23
*Dietary data or blood samples were collected before (Prospective P) or after (Retrospective R) the development
. of the cancer.
tRelative risk is presented so that risk in group with highest intake or blood levcl is 1.0, case-control
difference is intake or. blood level in cases relative to controls.
OControls not matched for smokini.
§NS. not si~nificant, carotene was protective in Anglos who were ex-smokers rather than in hispanlcsor current
smokers.
**Relationship seen in
ttEssentially an index
flflResults inconsistent
men but not women.
of beta-carotene.
between soxes, cases had a much lower intake of vitamin A fromsupple~ents.
m
co
'I
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that shows the
(9,16,22,23) .
stronger relationship with lung cancer risk
GASTROINTESTINAL CANCER
With the exception of one study (18), a low beta-carotene
intake is frequently associated with stomach cancer (Table 2).
Hirayama (28) reported from Japan that in areas where consumption
of yellow and/or green vegetables is high, mortality rates for
. stomach cancer tend to be low «r == -0.389, P < 0.05).
As with lung canCer the true protective factor is more likely
to be beta-carotene than total vitamin A. Thus, Stehr (27) found a
weaker relative risk for low total dietary vitamin A than for
beta-carotene, while Nomura et al. (13) saw no relationship for
serum retinol. However ,...the confounding role of- retinoLand_- of
other_factors,- parti-cularly vitamin C and smoking, requires further
clarification.
. ._0
.)
There is no evidence that beta-carotene has a significant role
in human colorectai cancer (Table 2). The detailed analysis
carr"lec]:-out--by-Kun.e.-et--ar;-(29) indicated that the increased risk
associated with a reduced beta-carotene intake is an artifact
aQsil}g_.frol'!! the. close relationship between beta-_ca~oterie--and
vegetables. --.-
Furtper, a retrospective study in Israel of gastro-intestinal
c<!n.9~r__with. .406 male ~I1c:J_.female cases, of WhO:m.-38.% ..had__~to.m~.c.h
sancer_and-.28%.<;:.9.lorectaL ciiric'er,'were
.
compared with B12'controls
(31). No association was seen with dietary carotene.
FEMALE REPRODUCTIVE CANCERS
Ovarian cancer appears to be associated with a low intake of
beta-carotene, but only in younger women (Table 3). Beta-carotene
also. seems protective. against breast cancer, particularly in
past.:menopausalwo-m-en (Table--3). '.Neilher the ovarian cancer study
(32) nor the .Guernsey study (34) saw a relationship for retinol
status thus indicating that in each cancer beta-carotene
specifically is the protective factor.
With cer'y.ical_cilnc.er,L_.:thepicture is unclear. Whereas the
Roswell Park (18) and Atlanta ~tudies(35)-s2~-nClrelationsh~or
diet.:g:y.totaL vitaf!1~n.~!J the Bronx (36) and Milan O,l$tudies
report that dietary beta-carotene had a strong inverse relationship
with risk. The Milan study--iI;; probably-t.~most~reliable report
due to-its size, its focus on beta-carotene, and its allowance for
the numerous confounding variables. It also showed an absence of a
relationship for dietary retino),. Thus, a low beta-carotene-intake
is probaoly-a.r"i"sk-factor--;-but this requires further investigation.
Cancer
stomach
stomach
stomach
stomach
stomach
colorectal
colorcctal
colon
rectum
colon
rectum
colorectal
TABLE 2
*Relationship Between Measures of Beta-carotene Status and Risk of Gastrointestinal Cancer
Heasurement
dietary total
vitamin At
dietary beta-
carotene
ye llow/ ~reen
vegetables
serum beta-
carotene
plasma beta-
carotene
plasma beta-
carotene
serum beta-
carotene
dietary total
vitamin At
dietary beta-
carotene
colorectal dietary beta-
carotene
colorectal dietary total
carotene
No. of
cancers
and sex
179 M
83 F
No. of
controls
not
111H/F stated
1238
1680
70 H
3913 M/F 265,118
302
19M
14M
113M
219 H
300 M
241 F
217 F
388 M
327 F
245 M
174.F
49M
37
33
302
1238
1680
398
329
489
345
1954
Type of
study
R
R
p
p
p
p
P
R
R
R
p
Relative risk or case-control
difference
0.9, 0.6, 1.0 (NS)
0.8, 0.8, 1.0 (NS)
2.0, 1.0
1.3, 1.1, 1.0 (p < o.00015)'
21% lower .(NS)
33% lower (NS)
21% lower (NS)
15% lower (NS)
1.0, 1.0, 1.0
1.1, 0.9, 1.0
0.8, 0.8, 1.0
1.3, 1.3, 1.0 (NS)
6% lower (M) or 11% lower (F)
(p
< 0.01 1n each sex)
1.2, 0.9, 0.8, 0.8, 1.0 (NS)
0.6, 0.5, 0.6, 0.6, 1.0 eNS)
7% higher (NS)
*Detailsas Table 1. In some cases data on colon and rectal cases have been merged.
tEssentially beta-carotene.
Place
Roswell Park
Pennsylvania.
Ja.pan
Hawaii
Basel
Basel
Hawaii
Roswell Park
Melbourne
Adelaide
Chicago
Reference
18
27
28
13
12
12
13
18
29
30
9
OJ
IT!
-t;po
I
n
:x:o;0
0
-tIT!
:z:
IT!
:x:o
z
0
n):.
2:
n
I'T1;;IJ
0'1CD
\0
TABLE 3
*Relationship Between Measures of Beta-carotene Status and Risk of Female Reproductive Cancers en\0
0
No. of
cancers No. of . Type of Relative risk or case-control
cancer' Measurement and sex controls study difference Place Reference
ovary dietary beta-
93t #carotene 383 R 2.3, 1.4, 1.0 (p<O.Ol) Roswell Park 32
breast dietary total
**vitamin A§ '1025 475 R 1.5, 1.4, 1.4. 1.0 (p<0.05)tt Roswell Park 33
breast plasma beta-
39 tillCl\rotene 78 P 2.8, 1.9, 2.4, 2.1, 1.0 (NS) Guernsey. Isles 34
uterus dietary total
vitamin A§ 422 1680 R 1.2, 1.1, 1.0 (NS) RoswellPark 18 :z.Co.
cervix dietary total .
vitamin A§ 947 1680 R 1.1. 1.0. 1.0 (NS) Roswell Park 18 -(f'T1intra- :3:
epithelial dietary total ""0r
neoplasia vitamin A 50 50 R 5% higher (NS) Atlanta 35 f'T1
~of cervix :;]
0-
severe
dysplasia dietary beta-
-(
'"or carotene 25 82 R 3.1, 1.0 (p < 0.01) Bronx, NY 36
carcinoma co
in situ of :t-V)
cervix c::
invasive
cervical dietary beta-
cancer carotene 191 191 R 6.6. 3.0. 1.0 (p < 0.001) Milan 37
*Details as Table 1.
tSubjects are age 30-49.
HAfter multiple regression the relative risk is reduced but is still significant (p < 0.05).protectionot seen at
age 50-79 (181 cases vs 651 controls).
§Essentially beta-carotene.
**subjects are age 55 or over.
ttProtectlon not seen at age under 55 '(999 cases vs 988 controls).
. tlflSubjects are half pre- and half post-menopausal.
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OTHER CANCERS
Prostate cancer presents an inconsistent picture (Table 4).
Thus there are two studies in the u.s. which have indicated that a
high intake of vitamin A may actually be a risk factor (38,39)
whereas another study in Japan suggests that yellow and/or green
vegetables are protective (21).
There is_limitedLevidence that be~~oten~may be protective
against cancer of the larynx, tongue, esophagus and bladder (Table
5) but in each case the confounding effects of other factors such
as retinol and vitamin C needs elucidating (13,18,40-42).
EXPERIMENTAL TUMORS
Beta-carotene has demonstrated a preventive action against a
variety of tumor types (Table 5). We (45) recently showed that in
mice treated with 1,2-dimethylhydrazine (DMH) beta-carotene causes
a fall in tumor incidence by about half (96% for adenocarcinomas,
,40% for adenomas). Tumor multiplicity was similarly reduced.
Mouse mortality, measured from the time when tumors were already
present, also fell by about half. The dose of beta-carotene (20
mg/kg diet) is equivalent to about 150 to 300 g carrots per 3000
~cals, ahd is therefore in the nutritionally relevant range. It is
the lowest dose yet shown to be anti-carcinogenic. However, a
s~milar- experil!\~_t on rats show~~ _n9__r~~c~~ the yield of
tumo.a>--.in-thecolon~and-smalT--intestine (46). There are several
elifferences -betweenth~s experimelit---ana ours, which might account
for these contradictory findings. The rat study used a 500 times
higher dose of beta-carotene, the species difference, and their
control group had a tumor incidence of 100% (versus 74% in our
study).
Several studies (47-50) have provided firm evidence that
beta-carotene prevents skin tumors (Table 5). In each case the
~~~_leY~L-of beta~arotene-u~d was many times greater than can be
ol2..tained from nat~.al---foods. It.__is-unc.lear how..mucn_of this
protecti-on-i's-specif..!e-to_the carcinogenic action of UV light.
These experiments hold much ~1se-i'f-beta-carotene or, perhaps,
other carotenoides will prevent skin cancer in high risk
individuals, such as fair skinned people frequently exposed to
bright sunshine.
MECHANISM OF ACTION
An important question is whether beta-carotene is most
e f£e-cfi:ve at-'tne-inItia tion-or-prOiTiOtionS1::age-of-ca-rc inogenesis .
en
\D
N
. TABLE 4
*Relationship Between Measuresof Be ta-ca rotlme Status and risk of Various Cancers
No. of
cancers No. of Type of Relative risk or case-control
Cancer Measurement and sex controls study difference Place Reference
prostate dietary total #
vitamin At 311 M 294 R 0.6, 0.8, 1.3, 1.0 (p<O.OI) Roswell Park 38
prostate dietary total 181 M 181 R higher by 207. (age 30-49; Washington 39
vitamin A p < 0.007) or by 137. (age 50 z
and over; p < 0.069) .
prostate green/yellow c....
vegetablcs 63 M 122,261 P 2.5, 1.6, 1.a Japan 21
~leukemia dietary total 130 M 1238 R 0.5, 0.7, 1.0 (p .. 0.01) Roswell Park 18 IT!3:
vitamin At 61 F 1680 0.8, 1. 1, 1.0 (NS) '"0
r-
larynx dietary total I'TI
vitamin At 338 H 359 R 3.0, 1.9, 2.1, 1.0 (p(0.OO5) Roswell Park 40 11>
tongue dietary total ~Q.
vitamin At 173 }! 1238 R 1.7, 1.3, 1.0 (p < 0.01) Roswell Park 18
-I('sopha~us dietary tot31 .:;w;:
vitamin At 147 t! 264 R 1.9, 1.6, 1.0 (p .. 0.033) Roswell Park 41 .
bbdder diet<lry total 489 MfF 901 R 2.1, 1.9, 1.7, 1.2, 1.4, 1.2, CD
vitamin At 1.0 (p < 0.01) Roswell Park 42
;r:.V)
bladder seTum beta- c::
carotene 27 11 302 P s<lme in cases and controls !lawai! 13
various green/YE:'llow 42 M/F§ 904 p 3.3, 2.7, 3.0, 1.3, 1.0 Massachusetts 43
ver:etables
"'*
(p < 0.01)
vi1rious serum total III M/F 210 P 0.7, 1.1,1.1, 1.1,1.0 various pillces 44
C,1rotene (NS)tt in
U.S.A.
*Deti1ils as Table I~
tP.ssentially betn~c3rotene.
PRisk was stronger at age 70 and. over than at age under 70.
§Cancer cases: breast 6, lung 10, intestine 4, other 22.
*"'Cancercases: breast 14, lung 17, ~astrointestinal 11, prostate II, leukemia
ttOver half of this relative risk for a raised serum carotene level comes from
and ly~phoma II, other 40.
leukemia and lymphoma.
House Dtm colon 20 tumor yield and mortality 45
reduced
Rat 0011
'"
colon and sMall intestine 10,ODD no efEec t 46
MOllse DMBA /UV/croton oil skin 33,000 delayed tumor appearance 47
200#
reduced tumor yieldt
tiouse DM~A/croton oil skin papillom:1 tumors regressed§ tt 48Mouse BP /UV skin ** reduced tumor incidence 49
!tous!' UV skin (squamous cell UR delayed tumor appearance 50 mf'TI
carcinoma) reduced tumor Rrowth rate -I:x:-
lIi1nster DHM/benzoyl peroxide Buccal pouch (topical) reduced tumor yield 51 I
n(epidermoid carcinoma) :x:-
Rat DMBA submandibular gland 5-250 delayed tumor appearance §§ 52 e:
reduced tumor size & incidence -4
90++ f'TIRat DMBA (ig) not specified reduced tumor incidence 53 z
1"'1
[)HBA Og) not specified 45-270
and multiplicity ++ 54 :t-Rat reduced tumor yield Z
Mouse oncogenic virus 90-120 delayed tumor appearance 55 c
reduced tumor incidence n:::»
improved tumor regression zn
~10use transplated 90 delayed tumor appearance 56 1"'1
adenocarcinomn decreased tumor incidence
::0
cells increased survival time
TABLE 5
Effect of Beta-Carotene on Experimental Carcino~enesis
Species Cancer lnducin~ Agent T\lmor Beta-Carotene
(mg/kg diet)
Effect Reference
*DHBA, 7,12-dimethylhcnz(a)anthracene.
tProtection scen hoth with A~d ~~t~nut UV.
URets-carotene nnt given until tumors alrcady present.
.Only5 mice in each of the 2 groups.
+RP. benzo(a)pyrene
**500 rng/kg diet plus 100 ~/kg body wt iR.
t tT\1!11orincidence reduced approximately 50% in firoup ~iven RP andUV bulonlya slight reduction in ~roup given BP alone.
##5-25 rng per mouse thrice weekly by ip injection.
§§25-250 mg/k~ doses were of similar effecliveness but 5 rng/kg was ineffective.
++Beta-carotene given only after carcinogen.
t+Beta-carotene supplementation stopped one day before carcinogen administration, all doses of beta-carotene gave a
similar response.
m\0
W
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The best evidence COmes from a hamster study which showed
beta-carotene to be clearly effective at both stages (51).
Similarly, beta-carotene was shown to inhibit DMBA induced
transformation of mouse mammary cells in vitro, with activity
apparently occurring at both stages (57). Other studies listed in
Table Shave indicated that beta-carotene can be effective when
given before the carcinogen (54), after the carcinogen (53) or else
after tumors are already present (48). The experiments using an
oncogenic virus (5S) and a transplantable tumor (56) point to a
late stage effect. In our mouse colon study beta-carotene did not
affect DMH induced colon mucosal hyperplasia, suggesting that the
protective effect occurred during promotion (45). In summary,
beta-carotene appears to block the initiation, promotion and
subsequent development of tumors.
There are several possible mechanisms to account for the
anti-carcinogenicity of beta-car9ten~.. It. may require. prior
co-nv;ersiOn-to=_~~tinol. However, this is a do"Ubtful-m6de 'of--action
in.
.
either-humans or--experimental animals. -As-noted-' earlier,
studies on human lung cancer strongly indicate that the protective
action of beta-carotene is not shared by retinal (9,12,13,15-23).
Weaker evidence suggests that this is also the case-in stomach and
cervical cancer (12,13,18,27,28,jS-37). Further experiments on
:r:ats.us'ing_.J:"e.t.inoLo~§!_~inoids have. seen, onlya much weaker
protective e.ff.ect (58-61). Similarly, the preventive acti'on of
beta-carotene against DMBA induced submandibular gland tumors of
rats (Table 5) is not shared by 13-cis-retinoic acid (62). The
study reporting that beta-carotene prevented DMBA ind~~edLin vitro
transformation of mouse mammary cells also observed that there was
no accumulation of retinol (57), and thus beta-carotene itself
seems to be the active compound.
If the anti-carcinogenic action of beta-carotene does not
depend on retinol formation, then carotenoids which lack
pro-vitamin A activity should also be anti-carcinogenic.
Canthaxanthin is such a carotenoid and does indeed protect mice
against skin tumor formation' (4 T, 49) . '., However, this may merely
reflect a specific protectiveehffect againsLUV':llght. In a trial
on Philipino betel ~ut and tobacco chewers, beta~carotene, but not
canthaxanthin, protected -against chromosome breakage in the oral
mucosal cells (63). Conceivably, beta-carotene has, sL-specific
anti-carcinogenic action-which is independent of.-its vitamin A
acti vi ty-,--and-.thi-s~action is not shared by other carotenoids.
Alternately, the anti-carcinogenicity of beta-carotene may reflect
its vitamin A activity but only in specific tissues.
We (64) recently observed that dietary beta-carotene alters
the hepatic levels of certain drug metabolizing enzymes. When mice
received supplemental beta-carotene (20-500 mgjkg diet), there was
a marked decrease in the activity of both cytochrome P-450 and
biphenyl 4-hydroxlyase, though not in antipyrine N-demethylase or
p-nitroanisole O-demethylase. Possibly this might cause
car"cinogens to be shunted along a detoxification rather than an
activation pathway. This, of course, presupposes that
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~eta~~~rotene- --is
carcinog_enesis ...
It has been suggested that beta-carotene may have an
anti-oxidant property, especially at the relatively low oxygen
partial pressures found in most tissues under physiological
conditions (65,77). The presumed mechanism is by trapping free
radicals. We investigated this by measuring two liver indices of
tissue oxidation, namely superoxide dismutase and malonaldehyde.
However, neither was altered by supplemental beta-carotene (64).
Similarly, the liver and plasma level of malonaldehyde in rats is
not altered by dietary beta-carotene (although, significantly, it
is increased by dietary 13-cis-retinoic acid) (66). On the other
hdnd beta-carotene protects guinea-pigs against chloroform induced
lipid peroxidation (67).
acti'{e durinq the initiation stage of
Another possible ~echanism of action of beta-carotene is by
enhancement of the immune defense (68). This concept is supported
by the fact that beta-carotene achieves at least part of its
protective effect in late carcinogenesis. The nutrient enhances
the immune response of rat colorectal tissue (Gg), increases the
cytotoxicity of macrophages towards hamster tumor cells (70) and
enhances thymic function, particularly lymphocyte production (55).
Beta-carotene also influences human interferon action, an effect
opposite in direction to that of retinoic acid (71,72).
COMMENT
The ideal strategy in the war on cancer is to learn how to
prevent it as well as cure it. In this regard beta-carotene is
"well on its way to being an important weapon. It appears to help
prevent several cancers, particulary of the lung. That it
apparently achieves much of its effectiveness in late
carcinogenesis is particularly valuable. There is ample
justification to recommend that the general population emphasizes
green and yellow vegetables. Quite apart from beta-carotene, they
also have many nutritional virtues.
While it is possible that.-beta-carotene -supp1ementation~may
have potential value t9-_4:!-.g"!1-risk individuals, there is still much
to be le"arned before recommemdation- can be made for the carotenoid
supplementation to prevent cancer. Animal experiments need to be
extended to cover more organ systems (very little has been done on
animal models of major human cancers). We need to know the
relative effectiveness of nutritional and pharmacological dosages
of beta-carotene, as well as the stage at which they work
(different dosages may work at different stages). Further
immunological work should prove profitab1e- "
Human studies, both diet and blood, have looked at either
beta-carotene specifically, or at total carotene. Blood beta-
carotene is only. 16% of total carotene (73). What is the
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importance of carotenes other than beta-carotene? There is still a
great need for human studies on the relationship between
carotenoids and cancer risk. We would urge anyone contemplating
such an investigation to study the papers by Peto et al. (l)! Peto
(74) and Palgi (3). Two primary prevention trials employing
beta-carotene supplements are currently in progress, one with
physicians in the U.S.A. (75) and another. on smokers in Finland
(76). Hopefully, the results will prove to be highly rewarding.
10.
11..
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